Mitchell Ho, PhD

Antibody Engineer | Biochemist | Dedicated to Improving Human Health | Senior Investigator, National Cancer Institute (NIH) | Views My Own

[Mitchell Ho, PhD @MitchellHo]

It is such an honor and privilege to work with a group of talented and dedicated trainees, colleagues and collaborators @NCIResearchCtr @IRPatNIH to develop new cancer therapeutic targets. @NanLizea @danli_502 @pan_jiajia @gerard_hoeltzel @CachauRaul

[Nature Communications @NatureComms]

Development and optimization of CAR T cells targeting glypican-1 for pancreatic cancer therapy.
https://t.co/MDU6ZWReaL #CancerResearch @natrescancer @MitchellHo @NanLizea @theNCI @NCIResearchCtr @IRPatNIH

[CAR T day @CARTday_]

🎉 It’s ON – CAR T day 2025 starts today!

📍 See you from 09:00 AM at the Faculty of Medicine – Research Center - 1 place de Verdun, 59000 Lille, France

🗓️ Check today’s highlights on the visual below 👇

For the full program 👉 https://t.co/OBNYEpAcuP

Let’s kick off two days of inspiring discussions, cutting-edge science, and valuable connections in the CAR T field! 💬🧬✨

#CARTday #CARTday2025 #CARcells #Lille2025 #InternationalEvent #eventprofs @CHU_Lille - @univ_lille - @sfiimmunologie - @i_yakoub_agha - @DrOlivierBoyer

[David R. Liu @davidrliu]

I discuss the urgent crisis from the loss of federal support of science in the US and recent clinical gene editing breakthroughs with @WalterIsaacson & @amanpour on @AmanpourCoPBS, airing on @PBS tonight at 11 pm ET, and on @cnni earlier today. Pls share!
https://t.co/cyVZpAwJiq

[Nature Reviews Cancer @NatureRevCancer]

🥳 Our 2nd most downloaded article in 2024:

Cancer therapy with antibodies by Paul, Gabelli, @MitchellHo, van Elsas & colleagues

https://t.co/J3O3OnSEjN

@JohnHopkins @theNCI @NIH @NatResCancer #NRCtop10of2024

[Mitchell Ho, PhD @MitchellHo]

It has been a great day! Thank you for inviting me to meet with wonderful faculty members and students at OSU and give a lecture at the Annual Meeting of the Pelotonia Institute of ImmunoOncology. @OhioStatePIIO @theNCI @NIH @IRPatNIH

[Pelotonia Institute for Immuno-Oncology @OhioStatePIIO]

Excited to feature Dr. @MitchellHo @NIH at #PIIO_2024 with his seminar: "Engineering #Antibodies and #TCells to Target #Glypicans in #Cancer". 6th Annual #PIIO Symposium.🧪✨

[Mitchell Ho, PhD @MitchellHo]

Honored to give a lecture at the Annual Meeting of the Pelotonia Institute of ImmunoOncology at Ohio State University @OhioStatePIIO @OSUCCC_James @Zihai @IRPatNIH @theNCI

[Zihai Li, MD, PhD @Zihai]

Great talk from @MitchellHo @NIH on engineering antibodies and T cells to target glypicans in cancer. @OhioStatePIIO @OSUCCC_James

[Pelotonia Institute for Immuno-Oncology @OhioStatePIIO]

Register today for the Sixth Annual Pelotonia Institute for Immuno-Oncology (#PIIO) Symposium! https://t.co/IqOqECvhTd

Dec 2-3, Vitria on the Square, 14 E. 15th Ave, 2nd Floor, Columbus, OH 43201 (across from Ohio Union)

[Mitchell Ho, PhD @MitchellHo]

Proud to listen to Dr Dan Li @danli_502 present our work on engineering T cells to target GPC3 in HCC at #ILCA24. @NCIResearchCtr @IRPatNIH @NCI_Training

[Mitchell Ho, PhD @MitchellHo]

Fantastic opening session “Bench To Bedside: Emerging Therapeutic Targets” #ILCA24 by @Valeriechew29 @TimGreten Dr Greten and I discussed basic and clinical research on liver cancer immunotherapy @NCIResearchCtr @IRPatNIH

[Mitchell Ho, PhD @MitchellHo]

Glad to share our new paper describing the discovery of a camel nanobody that mimics a TCR targeting the pMHC complex derived from an intracellular HPV tumor antigen and the generation of CAR-T cells against cervical cancer. @CSHinrichsMD @NCIResearchCtr @IRPatNIH

[Molecular Therapy Family of Journals @MolTherapy]

CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer through NFAT and NF-κB signaling https://t.co/I4nIv277vT

[Mitchell Ho, PhD @MitchellHo]

Happy to share our new research paper. We report for the first time the discovery of molecular interaction between GPC3 and AFP, both of which are specific proteins associated with liver cancer.
⁦@NCIResearchCtr⁩ ⁦@theNCI⁩ ⁦@IRPatNIH⁩ https://t.co/UJhmg1gSaE

[Mitchell Ho, PhD @MitchellHo]

Honored and humbled to receive the Asian American Engineer of the Year award. Will be giving a lecture on engineering antibodies and T cells to target glypicans in cancer. #AAEOY @NCIResearchCtr

[Journal for ImmunoTherapy of Cancer @jitcancer]

Let’s take a closer look at recent #JITC article: “rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors” by @MitchellHo & @danli_502 from @NCIResearchCtr & @NeoImmuneTech. 1/8

[Mitchell Ho, PhD @MitchellHo]

CAR T cells based on our humanized rabbit monoclonal antibody, called hYP218, targeting mesothelin epitope close to cell membrane, are very effective against mesothelin-positive tumors. @NCIResearchCtr @NIHClinicalCntr

[Molecular Cancer Therapeutics @MCT_AACR]

Anti-mesothelin hYP218 Chimeric Antigen Receptor T Cells—read this article featured in the AACR Journals Collection on Developmental Therapeutics.
https://t.co/GhrE9o9hpE
@MitchellHo #openaccess

[Freddy E Escorcia @freddyeescorcia]

🚨Latest paper just hit in @JournalofNucMed 🚨

It's got...
✅Single domain Antibodies.
✅PET imaging.
✅#LiverCancer

Buckle up! Thread time.
🧵
1/x
https://t.co/AaN4CSJjpQ

[Mitchell Ho, PhD @MitchellHo]

Our new study demonstrates that combination of an engineered IL-7 and CAR-T cells targeting GPC3, GPC2, and Mesothelin can greatly enhance anti-tumor activity in liver cancer, pediatric cancer and ovarian cancer. @NCIResearchCtr @NeoImmuneTech @danli_502

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors https://t.co/GSRTL517pT @MitchellHo

[Mitchell Ho, PhD @MitchellHo]

So proud of Laura Hutchins, a postbaccalaureate fellow in our lab @NCIResearchCtr @NIH_OITE, who was selected to give a talk #PEGSummit @PEGSboston for her work on a new antibody-directed TCR targeting GPC2 for treating neuroblastoma.

[Mitchell Ho, PhD @MitchellHo]

I am happy to share the latest review on cancer therapy with antibodies @NatureRevCancer @NCIResearchCtr. It was a pleasure to be part of the team led by Suman Paul and Shibin Zhou @JohnsHopkins

[Nature Reviews Cancer @NatureRevCancer]

NEW content online! Cancer therapy with antibodies https://t.co/MDBARsfWK0

[Mitchell Ho, PhD @MitchellHo]

Traveled to Beijing this week to give a keynote lecture at the Advanced Therapies Beijing Summit 2024. Had a great discussion with companies about collaborating on developing new cell therapies for treating liver cancer and other solid tumors.@NCIResearchCtr

[Mitchell Ho, PhD @MitchellHo]

@NCIResearchCtr @NIHClinicalCntr @theNCI Very honored to give a CCR Grand Rounds Lecture @NCIResearchCtr. Thank you to many colleagues @theNCI for joining in person or online! Looking forward to continued collaborations to use antibody and protein engineering for developing more active CAR-T and other immunotherapies

[Mitchell Ho, PhD @MitchellHo]

Very proud of Dr Dan li @danli_502, who received “Outstanding Postdoctoral Fellow Award” from Dr. Douglas R. Lowy @theNCI. She presented our new development of camel nanobodies and CAR-T cells targeting B7-H3 for treating cancer at CCR FYI Colloquium @NCI_Training @NCIResearchCtr